article thumbnail

Small Molecules Evolve

Drug Hunter

Small molecule drugs make up most of the drugs we take conveniently as pills, including painkillers like ibuprofen (Advil), antibiotics like penicillin and amoxicillin, or cholesterol-lowering drugs like atorvastatin (Lipitor). The small molecules drugs of today look nothing like the molecules of the 1970s.

article thumbnail

Small Molecule of the Year – 2022

Drug Hunter

Through a series of structure-based design, ADME and solubility optimization, LP0200 was shown to exhibit high potency and safety comparable to approved IL-17A and IL-17RA targeting mAbs (more in our report of first disclosures from the EFMC-ISMC and this article on small molecule immunomodulators ). LP0200 has completed a Ph.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

How to find a drug: the past, present and future of small molecule drug discovery?

DrugBaron

Despite the current hype around so called “advanced therapies”, which range from gene editing to cell therapies, and the inexorable advance of biologic therapeutics such as monoclonal antibodies, even in 2022 the majority of drugs in development and reaching patients are still small organic molecules.

article thumbnail

AI in Drug Discovery - A Highly Opinionated Literature Review (Part III)

Practical Cheminformatics

Following up on Part I and Part II, the third post in this series is a collection of review articles published in 2023 that I found helpful.

article thumbnail

Discovery of lirafugratinib (RLY-4008), a highly selective irreversible small-molecule inhibitor of FGFR2

Covalent Modifiers

Proceedings of the National Academy of Sciences 2024 , 121 (6), e2317756121. Gunaydin, H.; Boezio, A. McLean, T. Watters, J.; Bergstrom, D.

article thumbnail

Revolutionary molecular device unleashes potential for targeted drug delivery and self-healing materials

Science Daily: Pharmacology News

In a new breakthrough that could revolutionise medical and material engineering, scientists have developed a first-of-its-kind molecular device that controls the release of multiple small molecules using force.

article thumbnail

AstraZeneca and Regeneron to research, develop and commercialise new small molecule medicines for obesity

The Pharma Data

Novel small molecule drug candidates will target GPR75 to potentially address obesity and related co-morbidities. AstraZeneca has entered into a collaboration with Regeneron to research, develop and commercialise small molecule compounds directed against the GPR75 target with the potential to treat obesity and related co-morbidities.